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Abstract
Introduction: Cell therapy using adipose-derived stromal cells (ADSC) is an intensively developing approach to
promote angiogenesis and regeneration. Administration technique is crucial and among others minimal constructs
- cell sheets (CS) have certain advantages. Delivery of CS allows transplantation of cells along with matrix proteins
to facilitate engraftment. Cells’ therapeutic potential can be also increased by expression of proangiogenic factors
by viral transduction. In this work we report on therapeutic efficacy of CS from mouse ADSC transduced to
express human vascular endothelial growth factor 165 a/a isoform (VEGF165), which showed potency to restore
perfusion and protect tissue in a model of limb ischemia.
Methods: Mouse ADSC (mADSC) isolated from C57 male mice were expanded for CS formation (106cells per
CS). Constructs were transduced to express human VEGF165 by baculoviral (BV) system. CS were transplanted
subcutaneously to mice with surgically induced limb ischemia and followed by laser Doppler perfusion measurements.
At endpoint animals were sacrificed and skeletal muscle was evaluated for necrosis and vessel density; CS with
underlying muscle was stained for apoptosis, proliferation, monocytes and blood vessels.
Results: Using BV system and sodium butyrate treatment we expressed human VEGF165 in mADSC (production of
VEGF165 reached ≈ 25-27 ng/ml/105 cells) and optimized conditions to ensure cells’ viability after transduction.
Implantation of mock-transduced CS resulted in significant improvement of limb perfusion, increased capillary density
and necrosis reduction at 2 weeks post-surgery compared to untreated animals. Additional improvement of blood
flow and angiogenesis was observed after transplantation of VEGF165-expressing CS indicating enhanced therapeutic
potential of genetically modified constructs. Moreover, we found delivery of mADSC as CS to be superior to equivalent
dose of suspended cells in terms of perfusion and angiogenesis. Histology analysis of extracted CS detected limited
proliferation and approximately 10 % prevalence of apoptosis in transplanted mADSC. Significant vascularization of CS
and infiltration by monocytes were found in both – BV-transduced and control CS indicating graft and host interaction
after transplantation.
Conclusions: Delivery of ADSC by subcutaneous transplantation of CS is effective for stimulation of angiogenesis and
tissue protection in limb ischemia with a potential for efficacy improvement by BV transduction to express VEGF165.
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Introduction
Since the initial success of cell therapy for ischemic dis-
eases many attempts have been made to increase its
efficacy. Mesenchymal stem/stromal cells including
adipose-derived stromal cells (ADSC) are a promising cell
source for this application. ADSC are considered an at-
tractive candidate for therapeutic use because of their
availability (from subcutaneous fat), feasible expansion, and
established regenerative and angiogenic potential [1, 2].
Efficacy of cell therapy is defined by a whole spectrum
of factors ranging from cell type and origin [3, 4] to pas-
sage number and expansion conditions [5]. Recently
attempts have been made to enhance the therapeutic
properties of the ADSC modification approach to in-
crease secretion of growth factors and “tune up” the
paracrine effects, which play a cornerstone role in their
beneficial action [6, 7]. Growth factors production can
be increased by a spectrum of gene-delivery tools either
viral or non-viral [7]. Multiple studies and our own ob-
servations have shown that modification of ADSC does
not affect their differentiation and proliferation capacity
and may increase their therapeutic potential [8–10].
Choice of vector for gene delivery is a key point for
successful transduction of ADSC and we focused on
recombinant baculovirus (BV). BV is non-pathogenic in
mammals, induces transient (approximately 30 days)
production of protein [11, 12], and has minimal chance
of integration into host genome [13, 14]. BV-based
methods have been established for transduction of mam-
malian cells and optimized to achieve high expression
and prolonged production period [12]. In recent years
due to its properties and high transduction efficacy BV
has become a tool used in a wide array of applications
including vaccination [15], miRNA delivery for tumor
suppression [16, 17], etc.
Previously, we developed a recombinant system with
extended level and period of expression comprising two
BVs carrying cDNAs of: 1) human vascular endothelial
growth factor, 165 amino acid isoform (VEGF165)
flanked by FRT sequences, and 2) yeast FLP recombinase.
The effect of FRT/FLP relies on the generation of minicir-
cle DNA by FRT-targeted excision and has been utilized
to overexpress growth factors for ADSC-mediated bone
repair [9, 18] and cartilage regeneration [10] and to en-
hance cells’ regenerative and pro-angiogenic potency [19].
The second issue is method of delivery to the damaged
tissue, which may influence ADSC’s therapeutic efficacy.
It has been shown that injection of suspended cells
seems to have certain drawbacks. First, passage through
the needle or catheter may disrupt the cells mechanically
[20]. Another factor hindering survival of dispersed cells
is anoikis, which is apoptosis induction after loss of
contact with other cells [20]. Furthermore, after trans-
plantation cells may be exposed to an inflamed hypoxic
environment of damaged tissue, which results in drastic
reduction of their number and, thus, therapeutic effect
[21–23].
These described obstacles may putatively be circum-
vented by delivery of cells as minimally engineered con-
structs known as “cell sheets” (CS). This approach
relies on administration of expanded cells (in particular
ADSC) in a complex with extracellular matrix proteins
they produced after seeding at high density. CS can be
detached from culture dishes and transplanted to a
lesion as a whole-mount patch keeping cell-to-cell junc-
tions intact [24].
Application of CS to enhance cell survival found sup-
port in a comparative CS vs. injection study conducted in
a rat model of myocardial infarction. Using a biolumines-
cent method the authors reported higher survival of trans-
planted rat neonatal cardiomyocytes after CS delivery
compared to dispersed cell injection [25]. This observation
was concordant with better cardiac function in animals
from the CS group compared to rats treated with intra-
myocardial injection of cells in the same quantity.
Evaluation of ADSC-based CS in a rabbit model of
myocardial infarction showed its positive effects on left
ventricle geometry, ejection fraction, and vascularization
[24, 25]. Still another disorder afflicting a large cohort of
patients is peripheral artery disease (PAD) where cell
therapy has certain promise despite clinical trials, which
put its efficacy in doubt [26, 27]. CS-based methods
provide an excellent opportunity to improve cell therapy
for PAD and can be used during vascular grafting, re-
constructive surgery, and ulcer treatment.
In this research, we established conditions for mouse
ADSC (mADSC) transduction by recombinant BV. We
also developed a protocol for subcutaneous transplant-
ation of CS to mouse ischemic hind limb, which resulted
in significant improvement of perfusion. CS from
VEGF165-expressing mADSC showed improved thera-
peutic potential, which resulted in more effective restor-
ation of blood flow. Histological studies focused on CS
engraftment and induction of angiogenesis in skeletal
muscle. Our data provide novel insights into approaches
to enhance the efficacy of CS-based cell therapy of ische-
mic diseases because this study has been focusing on the




Dulbecco’s modified Eagle’s medium (DMEM), α-minimal
essential medium (α-MEM), 100× L-glutamine, 100× anti-
biotic/antimycotic solution were purchased from Gibco
(Gaithersburg, MD, USA); cell culture grade fetal bovine
serum and 0.25 % trypsin-EDTA solution were purchased
from HyClone (Logan, UT, USA); Grace’s insect medium
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was purchased from Sigma-Aldrich (St. Louis, MO, USA);
Hanks balanced salt solution (HBSS), Dulbecco
phosphate-buffered solution (PBS), Versene solution and
cell culture-grade 7.5 % NaHCO3 solution were purchased
from Paneco LTD (Moscow, Russia).
Histological and cell labeling dyes
Mayer’s hematoxylin solution was purchased from Dako
(Glostrup, Denmark), alcoholic eosin Y solution, trypan
blue 0.4 % solution and DAPI were purchased from
Sigma-Aldrich; Celltracker Green CMFDA and Red CM-
Dil vital dyes were purchased from Life Technologies
(Carlsbad, CA, USA).
Antibodies
Pharmingen® rat anti mouse PECAM (CD31) monoclonal
antibodies (Cat#550274) were purchased from BD Biosci-
ences (Franklin Lakes, NJ, USA); mouse polyclonal anti α-
SMA FITC-conjugated antibodies (Cat#F3777) were
purchased from Sigma-Aldrich; rabbit polyclonal anti
Ki-67 (Cat#ab16667) and rat monoclonal anti CD68
(Cat#ab5344) antibodies were purchased from Abcam
(Cambridge, UK); rabbit polyclonal anti cleaved caspase-3
antibodies (Cat#9664S) were purchased from Cell Sig-
naling Technology (Boston, MA, USA). Secondary
fluorescent antibodies AlexaFluor®594-conjugated don-
key anti rat (Cat#A21209) and AlexaFluor®594-conju-
gated donkey anti rabbit (Cat#A21207) were purchased
from Invitrogen (Carlsbad, CA, USA);. Vectastain ABC
kit (Rat IgG) (Cat#S-5000) was purchased from Vector
Labs (Burlingame, CA, USA) and used for visualization
of CD68 staining.
Animal strain and ethical approval
We used nine- to ten-week-old C57/B6 male mice for
ADSC isolation and hind limb ischemia model. Mice were
purchased from Puschino SPF-grade breeding facility
(Puschino, Russia). After acclimation, all animals received
standard food and water ratios according to in-house rules
of husbandry. Euthanasia was conducted after isoflurane
anesthetization by secondary cervical dislocation. Surgical
manipulations and euthanasia procedures were developed
in compliance with National and European Union direc-
tives and were approved by the Institutional Ethics Board
for Animal Care (Cardiology Research and Production
Complex; permit #385.06.2009).
Mouse ADSC isolation and expansion
Mouse adipose-derived stromal cells were obtained from
subcutaneous adipose tissue of male C57/B6 mice (eight-
to ten-weeks old) as previously described [8]. Isolated cells
were cultured in complete (10 % FBS) 4.5 g/L D-glucose
DMEM on uncoated Corning culture dishes under stand-
ard conditions at 37 °С and 5 % СО2. When reaching
80 % confluent monolayer mADSC were passaged at a 1:2
ratio after detachment by 0.05 % trypsin/EDTA solution.
For all experimental procedures, including CS generation
and preliminary testing, we used early passage (P3-P4)
mADSC.
Baculovirus generation and amplification in Sf9 cells
Generation and amplification of recombinant BV vectors
was conducted as described by Sung et al. [13, 19]. We
have used the following vectors: Bac-CE expressing
enhanced green fluorescent protein (eGFP) for cell
transduction efficacy assays; Bac-FCVW expressing hu-
man VEGF165 flanked by FRT and Bac-FLPo expressing
FLP recombinase for VEGF165 expression in mADSC
[28]. Stock BV at passage 1 was used for low-multiplicity
of infection (MOI) amplification by infecting insect Sf9
cells in Grace’s insect medium shaker culture. Endpoint
assay in Sf9 culture was used to determine amplified BV
titer [19].
Blood sampling
Blood was sampled from mice at days 0 and 7 of the ex-
periment with a 29G insulin syringe (BD Biosciences
(Franklin Lakes, NJ, USA)) by retrobulbar puncture. A
sample of 150 μl was drawn during ischemia induction
(day 0) and a sample of 300 μl was drawn prior to euthan-
asia at day 7. Blood samples were stabilized by EDTA and
centrifuged (5,000 g, 10 min) in a tabletop 5810R unit
(Eppendorf (Hamburg, Germany)) to obtain plasma for
ELISA.
Generation of cell sheets from mADSC
Cell sheets (CS) were generated in uncoated 12-well cul-
ture dishes from Corning (Corning,NY, USA). After
reaching 80-90 % confluence at P3, mADSC were de-
tached from 100 mm dishes by rinsing with 5 ml of Ver-
sene solution and short-term (1–2 min) incubation in
1.5 ml of 0.05 % trypsin/EDTA at 37 °С. By gentle tap-
ping, cells were detached, pipetted and diluted by 6.5 ml
of complete DMEM. A 30 μl aliquot was used for trypan
blue viability stain and manual cell counts using a
hemocytometer. Culture viability > 95 % was typically
observed at that stage. Suspended mADSC were centri-
fuged at 200 × g for 10 min, supernatant was aspirated,
and cells were suspended in complete DMEM to obtain
1.0 × 106 cells/ml density prior to seeding.
For CS formation, mADSC were seeded on a 12-well
plate at 0.5-1.0-1.5 × 106/well (well surface area = 3.8 cm2).
After seeding, medium volume was adjusted to 2.5 ml, the
plate was agitated by tapping to ensure even cell distribu-
tion, and incubated at 37 °С, 5 % СО2 for 24 hrs prior to
modification by BV.
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BV-transduction of mADSC
For evaluation of BV transduction efficacy we used a
monolayer of P3 mADSCs in a six-well plate, which
were infected by eGFP-bearing BV (Bac-CE) as follows.
Medium was aspirated, cells were washed by PBS twice,
and serum-free transduction solution (DMEM, α-MEM,
HBSS or PBS) containing Bac-CE (MOI 150 or 75) was
added in a total volume of 2.0 ml/well. After that the plate
was covered by foil to protect photosensitive BV and incu-
bated at 27 °С on a shaker for 3 or 6 hrs. After transduc-
tion cells were washed with PBS, complete DMEM was
added, and the cells were incubated for 15 hrs with so-
dium butyrate (NaBu) to obtain a working concentration
of 5 mM. After that, the cells were washed, medium
changed to complete DMEM, and the cells were incu-
bated for 48 hrs before fluorescence-activated cell sorting
(FACS) to evaluate eGFP expression.
To assess the influence of carbonate buffer on trans-
duction efficacy, mADSC were transduced by Bac-CE
(MOI 150) in HBSS mixed with 7.5 % NaHCO3 solution
to yield a final concentration of 1.0 or 3.0 g/l NaHCO3.
For transplantation to mice with induced limb ischemia
CS were formed from P3 mADSC in a 12-well plate at
1.0 × 106 cells/well density for 24 hrs. After that they were
transduced by Bac-FCVW/Bac-FLPo (MOI 150/15) in
HBSS for 6 hrs and treated by 5 mM NaBu (15 hrs) in
complete DMEM prior to detachment. Mock-transduced
CS and mADSC for injection in dispersed form were
treated by a mixture of HBSS and Grace’s medium from
uninfected Sf9 to imitate transduction conditions.
FACS analysis of eGFP expression in mADSC after BV
transduction
BV-transduced mADSC expressing eGFP were incubated
for 48 hours, detached, fixed with 1 % formaldehyde in
PBS and used for FACS to yield the percentage of eGFP-
positive cells and their mean fluorescence intensity (MFI).
Cell count and survival analysis
To evaluate changes in cell quantity during transduction
25 × 103 of mADSC (P3) were seeded on a 48-well plate
in complete DMEM, attached to plastic for 8 hrs, de-
prived for 4 hrs in serum-free DMEM, and then subject
to Bac-CE transduction (MOI 150, 6 hrs) in PBS or
HBSS. After transduction cells were washed, part of the
wells was used for manual cell counts using a hemato-
cytometer and trypan blue exclusion stain. Complete
DMEM with or without NaBu (5 mM) was added to the
remaining wells for 15 hours. Afterwards, cells were de-
tached to obtain endpoint cell counts. Untreated
mADSC in complete DMEM were deprived for 4 hrs in
parallel with experimental wells and served as a control
evaluated at the same time points.
ELISA for human VEGF165
We used the manufacturer’s protocol (R&D Systems
(Minneapolis, MN, USA)) for detection of human
VEGF165 in CS culture medium and mouse plasma
samples by ELISA using the corresponding Quantikine®
kit (Cat#DVE00).
Cell sheet labeling by CMFDA and CM-Dil
CellTracker green CMFDA was added to CS at working
1:2000 dilution to culture medium for 1 hr prior to de-
tachment and transplantation. Suspended mADSC were
labeled by CellTracker CM-Dil (Invitrogen) according to
the manufacturer’s protocol in PBS. Afterwards, CS or
suspended mADSC were washed and observed under a
fluorescent microscope prior to transplantation to en-
sure dye incorporation.
Detachment of cell sheets by trypsinization
CSs were washed with 2 ml of PBS twice and then once
with 2 ml Versene solution. After that, CS were treated
with 0.5 ml 0.025 % trypsin/EDTA per well for 15 sec,
washed with 2 ml of PBS twice and detached by tapping
and manipulation with a plastic disposable tip to induce
CS flotation (see Additional file 1: video 1).
Mouse hind limb ischemia model and CS transplantation
C57/B6 male mice (eight- to ten-weeks old) were narco-
tized by intraperitoneal injection of 2.5 % avertin
solution. All surgical manipulations were carried out in
aseptic conditions under a binocular microscope. Unilat-
eral induction of hind limb ischemia was carried out as
previously described [29]. Briefly, skin was incised along
the midline of the left hind limb and the femoral artery
with its branches was ligated between its proximal part and
popliteal bifurcation. The blood vessel was excised between
upper and lower ligatures with the sciatic nerve kept intact.
After that, the mock-transduced or VEGF165-epxressing
CS was transplanted in a drop of PBS to cover the site of
excised blood vessels and dried by a cotton ball. Animals
that received CS transplantation formed ADSC CS or
VEGF-ADSC CS groups (n = 7/group). In the untreated
control group (n = 9) the wound was rinsed with PBS
and dried. After CS adhesion (1–2 min) and control of
hemostasis, the skin was closed with 5–0 silk sutures
and the animals were placed in a chamber on a heated
pad until full recovery. Additionally, a group of mice
(n = 7) was injected with dispersed mock-transduced
mADSC diluted in 150 μl HBSS with a total of 1.0 ×
106 cells. Cells were delivered in three equal injections
of 50 μl each to the anterior tibia muscle, the femoral
biceps muscle and the femoral quadriceps muscle.
After surgery all animals received a 1.5 ml bolus of
warm sterile saline subcutaneously to compensate
blood loss.
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Laser Doppler perfusion measurement
Blood perfusion was assessed using a Moor LDI 2.0 sys-
tem in isoflurane-anesthetized animals after surgery and
at days 7 and 14 as previously described. Animals were
anesthetized by isoflurane inhalation and then placed on
a heating pad for ten minutes under 1-2 % isoflurane/
oxygen inhalation for stabilization of anesthesia depth and
blood pressure. Perfusion measurements on the plantar
surface of the animal’s feet (n = 3-4) were made and data
variability was analyzed using Moor image Review soft-
ware. Readings were taken until three subsequent runs
with minimal (<10 %) deviation were obtained. To ac-
count for variability among measurements, all ambient
light and temperature fluctuation readings were normal-
ized against non-ischemic limbs and expressed as relative
perfusion (%).
Microscopy procedures
Whole-mount microphotographs of the tibia anterior
muscle sections were taken with an Olympus binocular
microscope at low magnification using a CCD camera
and AxioVision 3.1 software from Carl Zeiss (Jena,
Germany). High power fluorescent and visible light
microimaging of sections was made on a Zeiss Axiovert
200 M fluorescent microscope with Axiovision 3.1 soft-
ware and a CCD camera.
Muscle harvest and hematoxylin/eosin staining
At days 7 and 14 animals from test groups were sacri-
ficed by lethal isoflurane inhalation. After skin dissection
the femoral quadriceps muscle covered by CS or injected
with mADSC was harvested and frozen in TissueTek
medium. The ischemic tibia anterior muscle was har-
vested for necrosis assessment and frozen in TissueTek.
Parallel frozen sections (7 μm) were prepared on glass
slides and stored at −70 °C. We used routine hematoxylin/
eosin staining for necrosis analysis in the tibia anterior
muscle and for detection of ADSC in the femoral quadri-
ceps muscle. Stained muscles were photographed as de-
scribed above and necrotic/infiltrated/viable tissue areas
were calculated using the color threshold function in NIH
ImageJ freeware. Obtained data were used for subsequent
statistical analysis after being normalized to section area.
Immunofluorescent staining and vessel density analysis
Sections were fixed in ice-cold acetone for 20 min, air-
dried and washed in PBS (5 min). All antibodies were di-
luted in blocking solution consisting of 1 % BSA in PBS.
After washing, slides were blocked by 10 % normal don-
key serum (30 min), washed, and incubated with rat anti
mouse CD31 antibody (1:100, 1 hr). Then slides were
washed in PBS (3 × 5 min) and incubated in a mixture of
anti rat AlexaFluor®594-conjugated antibodies (1:800)
and anti α-SMA FITC-conjugated antibodies (1:50, 1 hr).
At the end of incubation slides were washed, counter-
stained with DAPI (1:20000, 5 min), and mounted.
Microphotographs of sections were taken under 200x
magnification in five random fields of view (FOV) per
section. Vessel counts were performed blind by two in-
dependent persons using NIH ImageJ freeware. Capillary
density analysis included CD31-positive structures per
FOV; arteriolar counts per FOV were estimated as num-
ber of α-SMA-positive vessels with a clearly visible
CD31-positive inner layer. Capillary and arteriole counts
per FOV were pooled to obtain mean values and for
subsequent statistical assessment.
Ki-67 and cleaved caspase 3 immunofluorescent staining
Sections of the femoral quadriceps muscle covered by CS
were fixed in 4 % formaldehyde (20 min), washed in PBS
(3 × 5 min), blocked by 10 % normal donkey serum for
1 h, and incubated overnight with rabbit polyclonal anti-
bodies against mouse Ki-67 (1:50) or cleaved caspase-3
(1:50) at 4 °C. After washing in PBS (3 × 5 min), secondary
donkey anti rat AlexaFluor®594-conjugated antibodies
(1:800) were added for 1 h, slides were rinsed with PBS
and nuclei were counterstained by DAPI. Microphoto-
graphs were taken with 400× or 630× magnification using
immersion oil. Cells positive for Ki-67 and cleaved caspase
3 were counted manually and normalized to nuclei counts
per FOV to obtain the percentage of proliferating and
apoptotic cells.
Statistical analysis
Data are expressed as mean ± SD or SEM where appropri-
ate obtained from three or four serial runs per experiment.
The statistically significant difference between two groups
was determined using a Student’s t-test or Mann–Whitney
rank sum U test depending on sample distribution profile.
Multiple groups were compared using analysis of variance
(ANOVA) with Bonferroni correction for level of signifi-
cance where required (p < 0.05 was considered significant).
Wizard 1.6.2 and Statsoft Statistia 8.0 were used for ana-
lysis of obtained data.
Results
Rapid formation of cell sheets from mADSC
We observed rapid (within 12–24 hrs) formation of CS
from mADSC seeded to a 12-well plate at a density of ≥
1.0 × 106 cells/well (≈250 × 103 cells/cm2). Lower cell
density resulted in shattering of CS during trypsinization
or transfer to animal muscle. Morphology of cultured
mADSC changed drastically at density ≥500 × 103 cells/
well and was characterized by condensed, closely at-
tached cells. Interestingly, mADSC formed detachable
CS at 1.0 × 106 cells/well within 6 hrs post seeding, but
at 500 × 103 cells/well CS required at least 72 hrs of
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incubation to avoid disintegration and to be manipulated
by surgical tools (Fig. 1a).
We stained CS with cytoplasmic CMFDA dye prior to
trypsinization to perform visual assessment of floating
and attached parts of CS. We found no evidence for CS
disruption and established short-term (12–15 sec) treat-
ment with a low (0.025 %) concentration of trypsin/
EDTA as an appropriate method for CS detachment
(Fig. 1b). To analyze CS structure we prepared frozen
cross-sections of CMFDA-labeled CS formed from 1.0 ×
106 cells for 24 hrs. Our data suggest the CS has an aver-
age thickness of approximately 60–70 μm and consists
of three to six layers of cells (counted by DAPI-positive
nuclei) (Fig. 1b, right panel).
Influence of transduction medium and its buffer system
on BV-infection efficacy
Since specific surface markers of BV-entry permission
are yet to be identified [30, 31], while establishing a
transduction procedure one has to optimize conditions
depending on cell source, type, and medium used. Ini-
tially we analyzed the influence of medium, MOI, and
transduction duration using Bac-CE and FACS-analysis
of eGFP expression.
FACS analysis of mADSC transduced by Bac-CE for 3
or 6 hrs showed that use of PBS and HBSS for virus di-
lution resulted in a significantly higher percentage of
eGFP-positive cells (up to 85-95 %) compared to α-MEM
or DMEM (Fig. 2a). We found that MOI influenced the
percentage of eGFP-positive cells and in HBSS samples it
was significantly higher at MOI 150 compared to MOI 75
(91.9 ± 10.1 vs. 71.2 ± 9.5 %, respectively; p = 0.01).
Similar results were obtained during analysis of MFI
reflecting eGFP production. HBSS and PBS were also su-
perior to DMEM and α-MEM (Fig. 2a and b) suggesting
higher protein yield. MFI was at a plateau level and did
not change with MOI increment in cells transduced by
Bac-CE diluted in PBS and HBSS for 6 hrs (See Fig. 2b).
Fig. 1 Cell sheet formation and integrity of structure. a Upper row: images of mADSC seeded at various densities, 100× magnification (phase-contrast);
lower row: gross view of detached CS on forceps (left) and in PBS (middle and right). b. Images of detached CS from 1.0 × 106 of mADSC labeled by
CMFDA showing integrity of its floating part (left), attached part (middle), and its multilayered structure on frozen cross section (right, 200×
magnification, nuclei stained by DAPI). mADSC mouse adipose-derived stromal cells, CS cell sheet, CMFDA 5-chloromethylfluorescein diacetate,
DAPI 4′,6-diamidino-2-phenylindole
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After a 3 hr incubation with Bac-CE in PBS we found
MFI to be significantly higher at MOI 150, than at MOI
75 (Fig. 2b).
Among tested media, α-MEM and DMEM, which had a
lower efficacy, are carbonate-buffered solutions with 2.2
and 3.7 g/l of NaHCO3, while PBS and HBSS are based on
the buffering capacity of phosphates containing 0.0 and
0.35 g/l of NaHCO3. Supplementation of medium with
NaHCO3 is known to hinder BV entry [32], so we studied
its effect on mADSC transduction. Addition of NaHCO3
to HBSS (which showed optimal performance) resulted in
a drastic drop of eGFP-positive cells. Addition of 1.0 g/L
of NaHCO3 led to the decline of transduction efficacy
from 89.5 ± 4.2 % to 44.2 ± 6.5 % (p = 0.009) and at 3.0 g/l
NaHCO3 efficacy was even lower (29.5 ± 3.7 %). Based on
these data, in further cell survival analyses we focused on
phosphate-buffered transduction media and used HBSS or
PBS for virus stock dilution.
Cell survival after BV-mediated delivery of eGFP
High protein yield in BV-based procedures can rely on the
effects of sodium butyrate (NaBu), which is a non-specific
histone deacetylase inhibitor. It induces remodeling of
chromatin and can significantly boost protein production
yet exerts toxicity at high concentrations [33].
To assess survival of mADSC and effects of NaBu we
obtained manual counts of cells transduced in PBS or
HBSS with or without subsequent NaBu treatment. Prior
to BV-treatment all cells were deprived to limit the effect
of ongoing cell proliferation on count results. At the end
Fig. 2 Influence of medium, incubation time and MOI on transduction efficacy and eGFP production. a At both durations and MOI, maximum of
eGFP-positive cells was found after transduction in HBSS and PBS. b eGFP production evaluated by MFI correlated with transduction efficacy and
the amount of eGFP-positive cells showing PBS and HBSS to be similarly superior to DMEM and α-MEM. c Representative images of mADSC expressing
eGFP 48 hours after being transduced by Bac-CE in α-MEM and HBSS. * p < 0.025 vs. DMEM and α-MEM under similar transduction conditions;
& p < 0.05 vs. DMEM under similar transduction conditions; Mann–Whitney U test with Bonferroni correction. MOI multiplicity of infection, GFP
green fluorescent protein, HBSS Hanks balanced salt solution, PBS phosphate-buffered saline, MFI mean fluorescence intensity, DMEM Dulbecco’s
modified Eagle’s medium, α-MEM α-minimal essential medium, mADSC mouse adipose-derived stromal cells
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of transduction by Bac-CE (6 hrs) we observed a similar
15-20 % count decline (Fig. 3a: post TD), which tended
to be more prominent after transduction in PBS inde-
pendently of NaBu treatment. After mADSC were
washed and incubated with or without 5 mM sodium
butyrate from 15 hrs, cell number reduction was ob-
served in all samples (Fig. 3a: post NaBu). Still, mADSC
transduced in HBSS had significantly higher cell num-
bers than cells treated with Bac-CE diluted in PBS in
both NaBu-treated or control medium samples.
Extent of cell count decline was recalculated with the
initial 25 × 103 cells as 100 % (Fig. 3b). We found that
transduction in more nourished HBSS was able to
slightly mitigate effects of NaBu and cell count decrease
was similar in NaBu-treated and untreated samples
(−24.4 ± 5.3 % vs. -21.1 ± 7.8 %; p = 0.764). Unfortunately,
treatment of PBS-transduced cells with NaBu led to a
significant drop of cell number compared to NaBu-free
samples (−44.1 ± 5.4 % vs. -33.7 ± 4.4 %; p = 0.017),
which was not observed in HBSS. Based on these
Fig. 3 Cell survival after BV transduction in PBS or HBSS and stimulation with sodium butyrate. a Cell count dynamics over the time of the experiment
shows that use of glucose-containing (1.0 g/L) HBSS results in higher cell survival compared to PBS at endpoint (post NaBu). b Cell count decrement at
endpoint (18 + 15 hrs) expressed as percentage from initially seeded 25 × 103 cells. Mann–Whitney U test with Bonferroni correction, BV baculovirus,
PBS phosphate-buffered saline, HBSS Hanks balanced salt solution
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findings HBSS was preferred for transduction of CS pre-
pared for animal procedures.
Production of human VEGF165 by mADSC CS after BV-
mediated gene delivery
We have established a protocol for BV gene delivery of
VEGF165 to mADSC using HBSS for viral stock dilution
with 6 hrs of incubation. Treatment of 1.0 × 106 cell CS
from mADSC with Bac-FCVW/Bac-FLP at both tested
MOIs (75 or 150) resulted in onset of production of hu-
man VEGF165 as soon as 48 hrs post transduction
(Fig. 4) with MOI 150 yielding significantly more protein
of interest. Still, maximum amounts of VEGF165 at both
MOIs was detected after treatment of transduced cells
with 5 mM sodium butyrate reaching up to 27.2 ±
4,0 ng/ml/105 cells at MOI 150 (Fig. 4).
Subcutaneous transplantation of CS induces restoration
of hind limb perfusion
After mADSC were transplanted to ischemic muscle by
CS adhesion or intramuscular injection we observed no
limb loss or extensive necrosis throughout the experiment.
Transplantation of CS from mADSC (whether it was
transduced to express VEGF or not) resulted in increased
limb perfusion starting from day 7 (chart in Fig. 5). No
significant difference was found at day 7 between VEGF-
expressing and mock-transduced CS groups (44.3 ± 11.6 %
vs. 35.2 ± 11.1 %, respectively; p = 0.286). At day 7, only
the VEGF-ADSC CS group showed significant improve-
ment compared to untreated animals, which had relatively
low perfusion of 22.7 ± 8.5 %. By day 7, the ADSC-
injection group showed minor positive changes with an
average of 26.7 ± 5.3 % (p = 0.36 vs. untreated).
At the end of the experiment (day 14) both CS groups
displayed robust improvement of limb perfusion with
62.3 ± 6.8 % in VEGF-ADSC CS and 50.1 ± 6.5 % in ADSC
CS groups (p < 0.05 vs. 35.8 ± 6.6 % in untreated). Import-
antly, we found that endpoint perfusion in the VEGF-
ADSC CS group was significantly higher than in mock-
transduced CS (p = 0.038), which can be accounted for
VEGF165 production after BV modification. In our ex-
periment we found that by day 14 injection of dispersed
ADSC resulted in a moderate blood flowincrement (40.2
± 4.8 %) without statistical significance compared to un-
treated mice (p = 0.19). Moreover,animals that received
injection of dispersed ADSC showed lower perfusion than
animals that underwentADSC CS transplantation (p =
0.01).
mADSC are retained in skeletal muscle at day 14 after
transplantation by injection or CS delivery
During necropsy skin at the site of surgery was dissected
and carefully removed. We found that CS were adherent
to muscle surface, but not to dermal layers, which
allowed us to separate a part of the ,muscle together
with CS. At gross examination transplanted CS were
described as flat, opaque oval or disc-shaped structures
with uneven or barely visible margins covering the area
of the excised anterior femur. Microscopy of muscle sec-
tions at day 14 revealed CMFDA-positive cellular layers
adherent to the muscle (Fig. 6, lower row). As for
injected mADSC labeled by CM-Dil we found them to
reside within skeletal muscle resembling cellular infil-
trates located around myofibers in the middle portion of
the section near the injection site (Fig. 6, upper row).
Corresponding sections were also stained with H & E to
show that CS have a multilayered structure with a thick-
ness off 50–100 μm resembling a cross-section of de-
tached CS (Fig. 1b). Sections stained with H & E allowed
us to detect adherent grafts and were used for orientation
within the tissue sample (Additional file 2: Figure S1).
Induction of capillary angiogenesis in skeletal muscle
after CS transplantation
Histologic assessment of the anterior tibia muscle ex-
tracted at day 14 showed that capillary density was sig-
nificantly increased in both CS-treated groups compared
to untreated controls (Fig. 7). Analysis of sections
showed that in the ADSC CS group there was an average
of 224.3 ± 11.8 capillaries vs. 184.3 ± 10.6 in untreated
mice (p < 0.001). Maximum capillary density was ob-
served in the VEGF-ADSC CS group with an average of
255.6 ± 13.7 (p = 0.006 vs. ADSC CS and p < 0.001 vs.
the untreated control). Mice that received an injection
of dispersed ADSC had significantly lower capillary
density compared to ADSC CS animals with an average
of 194.5 ± 8.8 (p = 0.01 vs. ADSC CS). Moreover, to our
surprise, we found that after injection of dispersed
ADSC capillary density was just slightly higher, than in
untreated mice (p = 0.32 vs. corresponding control).
Fig. 4 Production of human VEGF165 by mADSC CS after transduction
by Bac-FCVW/Bac-FLPo. Culture medium samples were assayed 48 hrs
post transduction and VEGF165 concentration was normalized to cell
quantity after CS disruption by trypsinization. Mann–Whitney U test.
VEGF165 vascular endothelial growth factor, 165 amino acid isoform,
mADSC mouse adipose-derived stromal cells, CS cell sheet
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Another important characteristic of angiogenesis is
collateral remodeling or de novo formation of larger
blood vessels with mural α-SMA-positive smooth muscle
cells and inner lining of CD31-positive endothelium
(Fig. 7). Throughout the experimental groups we ob-
served similar density of α-SMA-positive vessels per
FOV: 3.31 ± 0.6 in untreated, 3.56 ± 0.4 in ADSC CS, 3.5
± 0.61 in ADSC injection group, and 3.41 ± 0.21 in
VEGF-ADSC CS (p > 0.05 in Kruskall-Wallis test). Thus,
we found no increment of arteriogenesis, which was
possibly attributed to a relatively early study endpoint
(14 days).
Reduction of muscle necrosis and inflammation after
ADSC delivery
The ability to prevent muscle necrosis is a crucial feature
of therapeutic intervention and evidence for adequate
restoration of blood supply.
For analysis we used the anterior tibia muscle, which
suffers from severe ischemia after anterior femur exci-
sion. Morphometric assessment of sections (details of
procedure can be found in Additional file 3: Figure S2)
indicated that in untreated controls the ratio of areas
covered by viable/infiltrated/necrotic tissue was close
to 1:1:1 (chart in Fig. 8). In the mADSC groups we ob-
served a drastic reduction of necrosis span from 26.3 ±
4.3 % in untreated down to 6.9 ± 2.0 % and 5.7 ± 1.9 %
in CS and injection groups, respectively; p < 0.001 for
both). Decrease of necrosis in VEGF-ADSC CS was
even more pronounced and this group had the lowest
number of necrotic fibers with a more than two-fold
decrease compared to the CS and injection groups (2.9
± 1.3 % vs. 7.2 ± 2.1 %; p = 0.005). Infiltration by inflam-
matory cells was also reduced in the ADSC CS and in-
jection groups resulting in 24.2 ± 5.7 % and 23.8 ±
5.1 %, respectively, which was in both cases lower than
in untreated control s(37.4 ± 4.6 %; p < 0.05 for both).
Moreover, in all ADSC-treated groups we observed a
significant increase in viable tissue, which indicated a
protective effect. The VEGF-ADSC CS group was char-
acterized by the highest amount of viable and healthy
tissue compared to other ADSC CS, injected ADSC or
untreated control groups (chart in Fig. 8).
Histology assessment of implanted CS vascularization
Engraftment relies on transplant vascularization; thus,
appearance of blood vessels within CS can serve as a
sign of successful implantation. Staining of the femoral
quadriceps muscle covered by CS revealed a number
of capillary-sized CD31-positive vessels within the
mADSC mass and sporadic α-SMA-positive larger
vessels. Vascularization of CS was found in all
Fig. 5 Effect of VEGF-expressing CS, mock-transduced CS or ADSC suspension on perfusion in the limb ischemia model. Presented Doppler images in
experiment group animals taken at day 14; chart reflects dynamics of limb perfusion in untreated negative control (n = 9) or animals that
received transplantation of VEGF-expressing (VEGF-ADSC CS, n = 7), mock-transduced CS (ADSC CS, n = 7) or suspended mock-transduced
mADSC by intramuscular injection (ADSC inj, n = 7). *p < 0.025 vs. untreated control; **p = 0.007 vs. untreated control and p = 0.038 vs. ADSC
CS; #p = 0.01 vs. ADSC injection. Mann–Whitney U test. VEGF vascular endothelial growth factor, CS cell sheet, ADSC adipose-derived stromal cells
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analyzed specimens (n = 2-3/group) with CS located
using parallel H & E slides or fresh sections of
CMFDA-stained CS.
A number of muscle fibers underlying CS had cen-
trally located nuclei indicating young skeletal muscle
fiber formation [34]. This suggests that CS-covered
muscle is capable of restoring its morphology after ini-
tial damage during surgical manipulation and subse-
quent ischemia.
Cell proliferation and apoptosis in transplanted CS from
mADSC
Cell fate after transplantation is always of crucial interest,
although its tracking is rather methodologically compli-
cated. We stained sections of femoral quadriceps muscle
with adherent CS for proliferation (Ki-67 antigen) and
apoptosis (cleaved caspase 3).
Figure 10a demonstrates CMFDA-labeled Ki-67-
positive cells, which are likely to be proliferating trans-
planted mADSC as well as intruder Ki-67-positive cells
without CMFDA label. Proliferating cells of both types
were found within CS in both ADSC CS and VEGF-
ADSC CS animals at approximately equal quantities at
day 14 after CS transplantation indicating proliferation
of transplanted CMFDA-positive mADSC as well as in-
vading host cells. Quantitative analysis of cells positive
for Ki-67 in acquired images indicated no significant dif-
ference in the prevalence of proliferating cells between
ADSC CS and VEGF-ADSC CS groups (6.28 ± 2.1 % vs.
6.01 ± 1.2 %, respectively; p > 0.05)
As for evaluation of apoptosis responsible for decline
of transplanted cells, we used cleaved caspase 3 antibody
(Fig. 10b). Cells showed both nuclear and cytoplasmic
localization of active caspase 3 indicating different stages
of apoptosis, yet we did not find any difference of apop-
totic cells in ADSC CS and VEGF-ADSC CS (12.5 ± 2.7 %
vs. 11.9 ± 4.2 %, respectively; p > 0.05).
Transplantation of VEGF-expressing CS does not result in
systemic dissemination of human VEGF165
In the VEGF-ADSC CS group ELISA of mouse plasma
drawn at day 7 did not reveal any detectable quantity of
human VEGF165. Values were below the level of detection
of the ELISA kit (not shown) and optical densities were
identical to values observed at day 0 (pre-transplantation
baseline). Thus, no evidence for systemic circulation of
human VEGF165 was found in our model.
Fig. 6 Retention of mADSC after subcutaneous transplantation of CS or intramuscular injection of dispersed cells. Prior to transplantation CS were
labeled by CMFDA (green) and dispersed mADSC – by CM-Dil (red) vital dyes. At day 14 after transplantation animals were sacrificed and skeletal
muscle samples were used for detection of ADSC retention at the site of delivery (on the surface of the femoral quadriceps muscle for CS or
within the anterior tibia muscle for injected mADSC). In the CMFDA-labeled CS, DAPI stain was omitted due to significant signal quenching after
washing of fresh sections in saline or fixation. Corresponding sections were stained with H & E to evaluate tissue status. mADSC mouse adipose-
derived stromal cells, CS cell sheet, CMFDA 5-chloromethylfluorescein diacetate, DAPI 4′,6-diamidino-2-phenylindole, H & E, hematoxylin and eosin
Makarevich et al. Stem Cell Research & Therapy  (2015) 6:204 Page 11 of 20
Discussion
In the last decade cell therapy of limb ischemia has been
extensively developed exploiting different cell types and
a variety of delivery methods. Still, the transplantation
procedure and its therapeutic efficacy remain issues
despite feasible access to skeletal muscle (compared to
myocardium or brain) and sophisticated guidance and
application techniques we dispose at the moment [35].
Our work reports a rapid and reproducible method for
generation of CS from ADSC and suggests aprocedure
for baculoviral expression of VEGF to enhance their an-
giogenic efficacy.
Formation of CS requires optimal conditions partially
depending on species due to cell size differences between
mammals (e.g., human ADSC are nearly three times as big
as mouse) and matrix synthesis rate. Our data confirmed
the role of optimal seeding density (Fig. 1a and b): forma-
tion of CS from mADSC was observed at 1.0-1.5 × 106
cells/well of a 12-well plate (≈250-375 × 103 cells/cm2),
which allowed the generation of a transplant with a sur-
face of 0.8-1.0 cm2. The latter was smaller than the well’s
bottom area due to surface tension-induced retraction of
CS. At lower densities formation of CS from mADSC may
require up to five days [24] and after seeding of < 500 ×
103 cells/well in a 12-well plate we incubated them for at
least three days to obtain a detachable structure (data not
shown). Thus, both approaches led to generation of CS
from mADSC, but a higher seeding density allowed reduc-
tion of time required for CS to form and become detach-
able. However, rapid generation relies on a large number
of cells, which is feasible for ADSC, but for other cell
types, which are not available in abundance or have lower
proliferation rate, this can be an obstacle and turn atten-
tion to long-term incubation.
Cell sheets from mADSC were detached using short-
term trypsinization without loss of integrity and comprised
a solid structure of approximately 50–70 μm thickness,
which accounts for three to six layers of cells (Fig. 1).
Most studies in the field exploit commercial or in-
house made thermoresponsive culture dishes [36, 37]
where detachment of CS occurs due to polymer coating
that changes its hydrophilic properties depending on
temperature. We had to omit use of thermoresponsive
dishes because the protocol for BV transduction in-
cluded 6 hrs of incubation at 27 °C, which resulted in
loss of adherence. This methodical hurdle was circum-
vented by application of short-term (10–15 sec) trypsi-
nization and also reduced the procedure’s cost by using
routine laboratory equipment to detach and manipulate
the CS (Fig. 1 and Additional file 1: Video 1).
We established a protocol for effective BV-transduction
of mADSC in HBSS with subsequent treatment by sodium
Fig. 7 Analysis of blood vessel density in skeletal muscle sections from study group animals. Histological studies of the anterior tibia muscle were
performed in samples harvested at day 14 of the experiment (n = 6/group): upper row – representative images of muscle sections from study
group animals stained for CD31 and α-SMA (magnification × 200); lower row – graphical presentation of blood vessel density analysis with average
group values per FOV; *p < 0.05 vs. untreated; **p < 0.025 vs. ADSC and Untreated; N.S. – not significant; Mann–Whitney U test with Bonferroni
correction. α-SMA, α-smooth muscle actin, FOV field of view, ADSC adipose-derived stromal cells
Makarevich et al. Stem Cell Research & Therapy  (2015) 6:204 Page 12 of 20
butyrate. Transduction of mammalian cells by BV is influ-
enced by a number of factors including temperature, pres-
ence of serum or other supplements and transduction
medium buffer system.
FACS-analysis of eGFP expression showed that BV-
transduction in PBS or HBSS resulted in up to 90 %
efficacy after 6 hrs of incubation at MOI = 150 (Fig. 2a).
Our data support the use of low-NaHCO3 media for viral
transduction of mADSC in the same manner as it was ob-
served by Shen et al. [32]. In our study use of α-MEM and
DMEM for viral stock dilution led to reduced
transduction efficacy, which correlated with higher
NaHCO3 content in these media known to hinder BV
transduction of mammalian cells. The negative influence
of NaHCO3 is attributed to its ability to reduce the
amount of BV entering the cell without significant influ-
ence on viral particles stability or binding to the cell mem-
brane [32].
Cell survival after BV transduction was assessed using
eGFP-expressing vector to avoid mitogenic or pro-survival
effects of VEGF165 and showed that use of HBSS is pref-
erable to PBS. Despite containing only 1.0 g/L D-glucose
Fig. 8 Reduction of skeletal muscle necrosis and infiltration after delivery of ADSC. Upper left – Whole-section images of hematoxylin/eosin-stained
muscle from corresponding study group; Upper right (a-d) Microphotographs representing histological changes in areas outlined in the upper row.
a Border area with necrotic fibers (N), inflammatory cells infiltrate (Inf) and viable tissue (V). b Artery-vein-nerve (star) complex with expressed
inflammatory extravasation. c and d Fibrotic tissue on site of resolved ischemic necrosis. Lower row Graphic presentation of morphometry
results; ANOVA and Student t-test with Bonferroni correction. ADSC adipose-derived stromal cells, ANOVA analysis of variance
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HBSS significantly attenuated toxicity of NaBu added to
the cells to boost protein production (Fig. 3). Thus, we
suggest that even minimally nourished HBSS mitigated
stress that mADSC underwent during transduction and
NaBu treatment so we used it in further procedures.
Expression of human VEGF165 in rodent ADSC using
the Bac-FCVW/Bac-FLPo system has showed its efficacy
in a rabbit model of myocardial infarction with a pro-
longed (>1 month) expression period in vitro [24] and
minimal immunogenicity in vivo [38]. In the current
work this approach has been successfully applied for
modification of high-density CS from 1.0 × 106 mADSC.
Our experiments suggest that maximum human VEGF165
output was achieved after transduction by Bac-FCVW/
Bac-FLPo MOI of 150/15 with subsequent NaBu treat-
ment resulting in VEGF165 content up to 25–27 ng/ml/
105 cells (Fig. 4). Still, protocols resembling ours are not
limited to application of BV for ADSC – due to the mech-
anism of BV entry after certain tests it can be adapted for
modification of other cell types. BV-mediated transduction
of chondrocytes [39], endothelial, cancer and epithelial
cells [40] has been reported to result in significant expres-
sion of the delivered gene. During development of new
approaches, NaBu treatment can be omitted in case of
prominent deteriorating effects on cell survival yet in
ADSC we managed to establish a “tempered” protocol
when application of appropriate medium (HBSS) and
other transduction conditions resulted in acceptable cell
survival along with peak VEGF165 production.
The method of transplantation we used requires routine
laboratory equipment for detachment and transfer of CS
and manipulations within the surgical wound were per-
formed in a drop of saline to reduce mechanical damage.
High adherence of CS to skeletal muscle allowed omitting
any additional material (e.g., fibrin glue). Furthermore, the
stickiness of CS was supported by histology findings at
day 14 that showed close contact of dye-labeled CS with
skeletal muscle (Fig. 6 and Additional file 2: Figure S1).
Interestingly, in CS-covered muscle we observed a num-
ber of young myofibers underlying the mADSC mass,
which raises a question whether myogenesis has been
supported by CS or was induced by surgical and ischemic
injury to the muscle.
The conventional method for ADSC delivery is injec-
tion of cells suspended in an isotonic vehicle solution.
Evaluation of dispersed mADSC engraftment after intra-
muscular injection revealed that dye-labeled cells resided
between myofibers at day 14 (Fig. 6). Labeled mADSC
located within the injection site were numerous indicat-
ing engraftment and survival, which is in accordance
with previous findings in BALB-C nude mice [8].
In the described case, the putative advantage of CS be-
sides transplantation of ADSC with matrix proteins is
the allocation of cells to the peripheral region of the
muscle (Fig. 5 and Additional file 2: Figure S1) where
the impact of inflammation and ischemia is not so
prominent. Indeed, in examined muscle specimens the
majority of viable tissue was located at the periphery,
whereas infiltration and necrosis occurred in the middle
portion (Fig. 8). In our experiments with BALB-C mice
suffering from extreme ischemia after surgery due to
weak collateral vascularization we found all central parts
of the section to consist of necrotic tissue in different
stages of disruption [8]. Thus, we may speculate about a
more “tranquil” environment for ADSC delivered on the
muscle surface compared to cells injected inside the ische-
mic tissue. However, injection of dispersed cells is feasible in
certain cases and can be easily adjusted for cell number,
injection count, and location and can be repeated over time.
Doppler measurements of limb perfusion showed that
transplantation of mock-treated CS led to a significant
improvement of blood flow compared to untreated con-
trols at day 14 and we also found ADSC CS to be super-
ior to injection of an equivalent dose of cells in terms of
limb perfusion (Fig. 5). Even higher perfusion was ob-
served in BV-transduced mADSC expressing VEGF165
suggesting that modification of CS improved its thera-
peutic efficacy and resulted in a better functional out-
come with relative perfusion reaching ≈ 60 %. To our
surprise, we found no significant improvement of limb
perfusion in animals injected with ADSC despite histology
studies revealing engraftment of injected cells. In this case,
a possible reason underlying this discrepancy may be dur-
ation of follow-up period. In our previous studies with in-
jection of cell suspension to ischemic limbs we found
maximum difference between control and treated mice at
20–21 days of experiment. At this time point, spontaneous
reperfusion responsible for restoration of blood supply in
untreated animals was at the plateau while treated animals
showed improvement [8, 29].
Overall, period of observation confines us to certain
boundaries and we cannot make claims about the ineffi-
ciency of injection delivery. The conclusion that can be
drawn from our study is that delivery of ADSC CS to is-
chemic limbs induces a faster perfusion rise compared to
dispersed ADSC. Still, further observation time points are
required to fully characterize the efficacy of both methods.
In limb ischemia models perfusion correlates with
blood vessel density and we assessed the influence of CS
transplantation on capillary and arteriole counts. We
found capillary-sized vessels increased in numbers after
transplantation of mock-transduced mADSC CS com-
pared to untreated controls (Fig. 7). Delivery of mADSC
by injection showed no significant effect on capillary
density and was inferior to CS delivery. This finding was
quite surprising as paracrine effects of ADSC are known
to induce angiogenesis within tissue, matrix, and other
animal models of vessel growth.
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Maximum increase in CD31+ capillary counts was
found in animals that received transplantation of
VEGF165-expressing CS, which may be accounted for
production of angiogenic growth factor known to in-
duce sprouting and vascularization [8, 41]. In these
specimens capillary counts were significantly higher
than in mice that received mock-transduced CS sub-
cutaneously. Observed changes in capillary density are
classic evidence of angiogenesis stimulation, accepted
since early work in this field [42]. Still, we did not find any
evidence for enhancement of arteriogenesis assessed by α-
SMA+ blood vessels in any study group (Fig. 7). This find-
ing emphasizes importance of expanded observation time-
frame as far as stabilization of largerblood vessels may
take up to three to four weeks in rodents [43].
Despite the obvious role of larger blood vessels for
perfusion, capillaries are known to be of crucial import-
ance for tissue nutrition [44] and do have an impact on
blood flow measured by Doppler-based methods [45].
Another mechanism of blood flow restoration relies on
collateral formation/remodeling, which may occur at the
proximal part of the limb and cannot be evaluated using
laser Doppler.
Observed improvement of blood flow was expected to
enhance muscle nutrition, which prompted histological
evaluation of the anterior tibia muscle (Fig. 8). ADSC CS
group animals showed reduced necrosis and infiltration
compared to untreated controls, whereas mice that re-
ceived VEGF-ADSC CS showed significant improvement
compared to untreated CS. Attenuation of necrosis is an
important endpoint in experimental [8, 29, 46] and clin-
ical studies on limb ischemia therapies [47, 48], thus,
this piece of evidence obviously supported the efficacy of
the developed technique. Conventionally used injection
of ADSC significantly reduced necrosis as well as muscle
infiltration (Fig. 8), which indicates that the antiapopto-
tic effect of this cell type takes place early after delivery
and may prevent necrosis and tissue disruption even
when vascularization has not yet been established. The
latter statement relies on lack of significant changes in
perfusion and vessel density in ADSC injected animals.
Still, it seems that when the cells are injected and, thus,
delivered to the epicenter of ischemia - the central por-
tion of the muscle – they manage to induce a paracrine-
mediated response and reduce the number of necrotic
fibers.
Transplantation of cellular grafts may induce an im-
mune response by the host and we evaluated infiltration
of CS by monocytes using immunohistochemical staining
for CD68. Monocytes (and their mature forms – macro-
phages and dendritic cells) are known to play a pivotal role
in resorption/phagocytosis, but also drive regeneration and
Fig. 9 Immunostaining for vascularization and monocyte invasion to transplanted CS. Images were acquired from CS and skeletal muscle sections
extracted at day 14 of the experiment and stained for blood vessel and monocyte antigens. a Representative image of blood vessels within CS
and corresponding H & E staining. b Representative image of larger blood vessels within transplanted CS (green arrow - α-SMA-positive blood
vessels; yellow arrow - α-SMA-negative). c Microphotographs illustrating CD68+ monocyte infiltration (DAB-visualized) to mock-transduced of
VEGF-expressing CS. d Graphic presentation of monocyte counts within CS from corresponding study groups; Mann–Whitney U test. CS cell sheet,
H & E hematoxylin and eosin, α-SMA α-smooth muscle actin, DAB diaminobenzidine, VEGF vascular endothelial growth factor
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control inflammation [49, 50]. Moreover, despite that the
stromal-vascular fraction may contain 10-15 % of the
monocytes [51], passaged ADSC are CD68-negative and,
thus, evaluation of monocyte infiltration would characterize
host response to delivered CS. We found up to 25 % of cells
within the CS were CD68-positive (Fig. 9c-d) indicating
their monocyte lineage and this figure was similar in both
BV-treated and mock-transduced constructs. This was an
encouraging finding showing that treatment of cells by
BV using our procedure did not enhance the
monocyte-mediated immune response to transplanted
cells. Moreover, VEGF165 itself may be characterized as
a cytokine with certain inflammation-driving modality
[52], yet we found no evidence for increased monocyte
invasion in VEGF-ADSC CS. Of course, immune re-
sponse to a graft may involve other cell types, especially
CD4+ and CD8+ T-cells, but our previous data in a
model of bone defect treated by BV-transduced ADSC
showed no significant difference in infiltration by these
immune cells [38]. Overall, these findings require add-
itional investigation in a more appropriate model as far
as use of inbred strain mice, which are close to the sib-
ling state, does not imitate allogeneic transplantation.
Retention of CS was found at days 7 and 14 and was
accompanied by vascularization of transplanted cell
mass by capillary (some had visible lumen) and spor-
adic α-SMA-positive blood vessels in most specimens
analyzed (Fig. 9). Formation of functional blood vessels
in CS has been previously observed in constructs from
endothelial cells [53, 54] and cardiac primitive cells
[55]. To our knowledge, this is the first report of blood
vessel formation within non pre-vascularized ADSC-
based CS in a model of ischemic pathology. Moreover,
the short-term CS formation used in our protocol and
use of non-angiogenic conditions (DMEM/10 % FBS,
normal O2 pressure, etc.) marginally excludes the possi-
bility of spontaneous pre-vascularization of CS during
in vitro preparation. The question to be addressed is
the origin of the CD31-positive endothelial cells in the
CS. Host blood vessel in-growth is the most obvious
answer, while ADSC are known to have a limited cap-
acity for endothelial differentiation [56] or can contain
Fig. 10 Proliferation and apoptosis of cells within subcutaneously transplanted CS. CS were stained by CMFDA and transplanted to mice
subcutaneously. At day 14, CS adherent to the femoral quadriceps muscle was extracted and stained for Ki-67 and cleaved caspase 3. Upper
row left and middle – CMFDA-positive (red arrows) and negative (yellow arrows) cells with Ki-67+ nuclei indicating proliferation. Magnification
400×. Lower row left and middle – representative images of cells positive for cleaved caspase 3 (white arrows). Magnification 630×. Right column
graphs illustrate results of manual count of proliferating and apoptotic cells in mock-transduced and VEGF-expressing CS; Mann–Whitney U
test. CS cell sheet, CMFDA 5-chloromethylfluorescein diacetate, VEGF vascular endothelial growth factor
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a small fraction of endothelial progenitor cells that may
contribute to vessel formation [57, 58].
We also obtained evidence for limited (6-7 % of total
number) proliferation of cells within CS, which was not
confined to transplanted mADSC. We found a number
of CMFDA-negative proliferating cells, which are likely
to be dividing host cells that invaded CS during engraftment
(Fig. 10). As for apoptosis prevalence, it was approximately
10-12 % in both – mock-transduced and VEGF165-
expressing CS (Fig. 10). To explain lack of difference be-
tween mock-transduced and VEGF-expressing CS we may
refer to our published in vitro data showing VEGF165
production reduces 12–14 days after transduction, [24] so
growth factor may not have had an impact on cell fate.
Observed vascularization of CS stressed in our study
provides mechanistic support for the efficacy of CS. We
can propose that paracrine activity of ADSC, which is
considered to be a driver of its angiogenic and regenera-
tive capacity [40, 59], may have an extended impact area
due to growth factor uptake through formed vessels.
This may explain stimulation of angiogenesis and reduc-
tion of necrotic alterations in the distal part of the limb
we used for histology evaluation. Another point support-
ing a paracrine mode of action in the CS-based protocol
is increment of its efficacy after VEGF165 expression in
the absence of reduced apoptosis or increased prolifera-
tion of transplanted mADSC. Because cell secretome
was the only parameter manipulated in this case, it is
very likely that growth factors and cytokines could be
the main mediators of efficacy.
Subcutaneous implantation of modified or xenogenic
CS has been utilized for creating cellular factories pro-
ducing FVIII in hemophiliac mice [54] or insulin in dia-
betic SCID mice [60, 61]. In these works the authors
observed a significant improvement of blood clotting
(with FVIII appearance) and euglycemia (with xeno-
genic C-peptide detectable) suggesting systemic uptake
of secreted factors from CS.
On the one hand, the abovementioned results provide
support for the possible concept of uptake of proteins
secreted by CS and, thus, may explain the efficacy of dis-
tant transplantation of CS. On the other hand, for
VEGF165 this could be considered a side effect due to
its tumor-activating potential and possible influence on
pathologic angiogenesis in retina, skin, etc. [62]. We per-
formed ELISA of plasma from mice at day 7 post-
transplantation of VEGF-expressing CS and did not de-
tect systemic circulation of human VEGF165.
The preliminary format of this research has also
revealed certain limitations listed below and hinting at
further study directions:
1) host/donor origin of vascular cells within CS – the
ADSC population mainly contains cells that carry
CD31 or may undergo endothelial differentiation
[63]; this requires clarification. This point can be
addressed using a sex mismatch approach in
further studies. Our data also indicate that in
angiogenesis models even CD31-negative ADSC
may incorporate (unpublished) or locate adjacent to
vascular structures acting as pericytes [63];
2) animal study duration – chosen terms of 14 days
were optimal for early stage evaluation of necrosis
and CS retention, yet extension of the experiment’s
time-frame would expand our knowledge of both
cell fate and CS effects on perfusion values and
vessel density;
3) syngeneic transplantation applied in the study is a
widely used model for autologous-based procedures
in recent years. However, allogeneic transplantation
is easier to scale-up and, thus, properties of allogeneic
CS may be of interest for development of clinically
relevant procedures. These studies would also provide
more valuable data on graft-host interaction;
4) ADSC grafting is donor-dependent so it could of
interest to evaluate the influence of aging, chronic
diseases and other factors on CS formation and their
regenerative properties [64].
Conclusions
Our study provides a rapid protocol for ADSC cell
sheet generation using routine equipment and opti-
mized conditions for ADSC baculoviral transduction to
express VEGF165. This modification results in significant
improvement of CS therapeutic activity and stimulation of
angiogenesis in ischemic skeletal muscle. Subcutaneous
transplantation of unmodified CS to ischemic limb was an
effective method for angiogenesis stimulation and tissue
protection. We suggest a paracrine mode of action for this
procedure and report no issues with systemic dissemin-
ation of VEGF165. Cell sheets from ADSC reside subcuta-
neously for at least 14 days and undergo vascularization,
infiltration by monocytes indicating interaction between
graft and host. We found no evidence for improved prolif-
eration or apoptosis prevalence in VEGF-expressing CS.
Additional files
Additional file 1: Video 1. Detachment and manipulation of cell sheets
from mADSC. Brief introduction to two critical points in ADSC CS
preparation – detachment using a pipette tip and manipulation in PBS
using a cell-strainer mesh glued to a steel spatula. (MP4 19296 kb)
Additional file 2: Figure S1. Examples of hematoxylin-eosin stained
sections of mADSC CS attached to mouse muscle. Low magnification
images show presence of CS on the femoral quadriceps muscle at day 14
(black arrows). (TIFF 3564 kb)
Additional file 3: Figure S2. Illustration for principle of morphometry
adopted in tissue section studies. Highlighted regions (bright red) of
necrotic and infiltrated tissue in a section of the tibial anterior muscle
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indicating color threshold selection of regions used for morphometry
(hematoxylin/eosin staining). NIH ImageJ freeware for Mac used for
processing. (TIFF 4432 kb)
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